<DOC>
	<DOCNO>NCT00005025</DOCNO>
	<brief_summary>RATIONALE : Gene therapy may make body build immune response kill tumor cell . PURPOSE : Phase II trial study effectiveness gene therapy treat woman refractory relapse ovarian epithelial cancer , fallopian tube cancer , peritoneal cancer .</brief_summary>
	<brief_title>Gene Therapy Treating Women With Refractory Relapsed Ovarian Epithelial Cancer , Fallopian Tube Cancer , Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy safety vivo gene therapy herpes simplex thymidine kinase ( HSVtk ) vector producer cell ( VPC ) follow ganciclovir woman refractory relapse ovarian epithelial adenocarcinoma , fallopian tube cancer , peritoneal cancer . - Determine development systemic immunity regimen tumor patient . - Determine toxic effect intraperitoneal HSVtk VPC patient . OUTLINE : All patient receive intraperitoneal catheter prior infusion . Patients receive herpes simplex thymidine kinase ( HSVtk ) vector producer cell ( VPC ) IP 15-60 minute day 0 , follow ganciclovir IV 2 time daily day 28-41 . Treatment repeat 3 course patient stable responsive disease . Patients follow every 3 month 1 year . PROJECTED ACCRUAL : A total 14-20 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm , refractory relapse , ovarian epithelial adenocarcinoma , fallopian tube cancer , extraovarian peritoneal cancer curative therapy exist Must tissue available tumor biopsy grow tumor cell ex vivo Must fail standard therapy platinum agent ( cisplatin carboplatin ) paclitaxel Site disease must less 5 cm great diameter Evaluable disease CT scan , physical exam , laparoscopy No significant peritoneal fibrosis either disease prior surgery Surgical lysis adhesion allow PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC great 2,000/mm3 Absolute neutrophil count least 1,000/mm3 Platelet count least 50,000/mm3 Hemoglobin least 8.5 g/dL ( without transfusion ) Hepatic : Bilirubin great 2.0 mg/dL SGOT SGPT great 4 time upper limit normal ( ULN ) Alkaline phosphatase great 4 time ULN Hepatitis B surface antigen test require prior study transaminase great 2.0 time ULN No hepatitis B surface antigen Amylase normal PT PTT normal Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No cardiac dysfunction history exam No ischemic heart disease may consider anesthetic operative risk Pulmonary : No lung disease may consider anesthetic operative risk Other : HIV negative Not pregnant nurse No acute viral , bacterial , fungal infection require medication within 14 day prior study No patient great 2 L ascites time intraperitoneal infusion No underlying condition would preclude compliance No allergy study reagent PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics Other : No concurrent high dose vitamin regimen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>